NASDAQ NMS - GLOBAL MARKET · EXEL

+0.00% · +$0.0000 · Vol Not reported

Market closed · last close shown

Exelixis Inc

Biotechnology

$54.08

Card

Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factors

Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET · EXEL

Methodology

EXEL

Exelixis Inc

Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET

59/100

NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100

Veridion Score

NEUTRAL · HIGH confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is EXEL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move EXEL next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 21
Score
Score moved -23
82/BUY BIAS -> 59/NEUTRAL
Veridion score historySource
Jan 10
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 6
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jan 8
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 4
CongressChecking access
Donna Shalala sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Apr 16
CongressChecking access
Donna Shalala sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Feb 6
CongressChecking access
Donna Shalala purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jan 9
CongressChecking access
Donna Shalala purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Oct 25
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Exelixis Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

2000

Employees

Country

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$54.08

Last session

Day high

$54.08

Last session

Day low

$54.08

Last session

Previous close

$54.08

52W high

$57.10

-5.29% from high

52W low

$34.54

87% of range

Market cap

$13.4B

P/E

18.33×

EPS

$2.95

Beta

0.52

Shares out

247.8M

Avg volume

2.5M

VWAP

$54.08

Last session

Price history computed in-house

+3.36%

-2.33%

+8.20%

+39.99%

YTD

+23.39%

SMA 50 $54.24 · below

SMA 200 $46.90 · above

52W position 87%

EXEL overview

Veridion Score

Registered · 2026-08-21

6 of 6 factors measured

Relationship mapTrace receipt-backed holders and filings around EXEL.Congress disclosuresOpen receipt and filing context for EXEL.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

EXEL insider activity

Exelixis Inc

Score

Not evaluated

Pressure

Not evaluated

Filings

Buys / sells

0 / 0

Net value

Not evaluated

Insiders

Cluster

Not evaluated: the SEC filing index could not be read

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

No value-bearing Form 4 rows

The current Form 4 feed did not return value-bearing open-market rows for EXEL.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in EXEL

Congress tracker Open ticker disclosure ledger →

Ro KhannaSell

EXEL Common Stock · Transaction Jan 10, 2024 · Filed Feb 5, 2024 · Amount pending receipt enrichment

Official filing ↗

Ro KhannaBuy

EXEL Common Stock · Transaction Dec 6, 2022 · Filed Jan 6, 2023 · Amount pending receipt enrichment

Official filing ↗

Ro KhannaSell

EXEL Common Stock · Transaction Jan 8, 2020 · Filed Feb 10, 2020 · Amount pending receipt enrichment

Official filing ↗

Donna ShalalaSell

EXEL · Transaction Jun 4, 2019 · Filed Apr 27, 2020 · $1,001 to $15,000

Official filing ↗

Donna ShalalaSell

EXEL · Transaction Apr 16, 2019 · Filed Apr 27, 2020 · $1,001 to $15,000

Official filing ↗

Federal contracts

EXEL contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for EXEL in this window.

Lobbying spend

EXEL lobbying filings, year to date.

Registered lobbying filings matched to Exelixis Inc.

$2.6M

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Taxation/Internal Revenue CodeTaxation/Internal Revenue Code Health Issues

Filing

$560.0K

EXELIXIS INC.

Jul 20, 2026

Filing

$520.0K

EXELIXIS INC.

Apr 20, 2026

Filing

$510.0K

EXELIXIS INC.

Jan 20, 2026

Analyst ratings

Sovereign unlock shows live analyst consensus for EXEL.

Options

Sovereign unlock shows live options positioning for EXEL.

Related tickers

Cross-references from this score page.

Apprentice · 1 rail

Similar headline score

Nearest public composite scores. Factor similarity requires Sovereign.

Why is EXEL moving today?

What can move EXEL next.

EXEL overview

Related filings and maps

EXEL insider activity

EXEL contract awards, year to date.

EXEL lobbying filings, year to date.

Cross-references from this score page.

What can move EXEL next.

EXEL insider activity

Cross-references from this score page.